Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis
ConclusionAll antihypertensive medication classes seem to exert neutral or insignificant effects on EF. Further high-quality studies are needed to better explore the effects of antihypertensive medication on EF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 4, 2021 Category: Cardiology Source Type: research

The Redox Modulating Sonlicromanol Active Metabolite KH176m and the Antioxidant MPG Protect Against Short-Duration Cardiac Ischemia-Reperfusion Injury
ConclusionProtection against cardiac IRI by the antioxidant KH176m is critically dependent on duration of ischemia. The data suggest that with longer ischemia, the capacity of KH176m to reduce cardiac oxidative stress is rate-limiting, irreversible ischemic oxidative damage maximally accumulates, and antioxidant protection is strongly diminished. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 29, 2021 Category: Cardiology Source Type: research

CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
AbstractPurposeThe CD36 scavenger receptor is a mediator of both atherogenesis and thrombosis. We aimed to investigate the prognostic value of CD36+ microparticles (MPs) released from platelets for cardiovascular event presentation in coronary artery disease (CAD) patients and the effects of different antiplatelet drugs on MPs.MethodsA total of 101 aspirin-treated CAD patients, who were planned to undergo coronary angiography (CAG), were randomized to either a standard clopidogrel regimen or ticagrelor treatment. Total Annexin V-(AV)+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs were quantified by flow cytometry at baseline...
Source: Cardiovascular Drugs and Therapy - April 24, 2021 Category: Cardiology Source Type: research

Ang II Promotes SUMO2/3 Modification of RhoGDI1 Through Aos1 and Uba2 Subunits, and then Regulates RhoGDI1 Stability and Cell Proliferation
ConclusionThis study reveals the differences between SUMO2/3 and SUMO1 modification in regulating RhoGDI1 stability and Ang II-mediated cell proliferation.Graphical abstractSchematic summary of roles of SUMO1 and SUMO2/3 modification of RhoGDI1 in regulating RhoGDI1 stability and cell proliferation in Ang II-treated HA-VSMCs. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 23, 2021 Category: Cardiology Source Type: research

Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy
ConclusionEmpagliflozin attenuates LV enlargement in mice with hypertrophic heart failure. This effect may be mediated, at least in part, by a reduction in loading conditions which limits upregulation of the inducible, proinflammatory, and prohypertrophic TNF superfamily receptor, Tnfrsf12a. Disruption of the Tnfsf12/Tnfrsf12a feed forward system may contribute to the cardioprotective benefits of SGLT2 inhibition.Graphical abstract (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 22, 2021 Category: Cardiology Source Type: research

An Adapted Neural-Fuzzy Inference System Model Using Preprocessed Balance Data to Improve the Predictive Accuracy of Warfarin Maintenance Dosing in Patients After Heart Valve Replacement
This study aimed to create an adapted neural-fuzzy inference system (ANFIS) model using preprocessed balance data to improve the predictive accuracy of warfarin maintenance dosing in Chinese patients undergoing heart valve replacement (HVR).MethodsThis retrospective study enrolled patients who underwent HVR between June 1, 2012, and June 1, 2016, from 35 centers in China. The primary outcomes were the mean difference between predicted warfarin dose by ANFIS models and actual dose and the models ’ predictive accuracy, including the ideal predicted percentage, the mean absolute error (MAE), and the mean squared error (...
Source: Cardiovascular Drugs and Therapy - April 20, 2021 Category: Cardiology Source Type: research

Correction to: Role of Bempedoic Acid in Clinical Practice
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07188-w (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 19, 2021 Category: Cardiology Source Type: research

Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis
ConclusionsThe use of a fixed-dose of 4-PCC may be considered an effective and safe dosing strategy for VKAs reversal in various clinical situations. However, further well-designed, controlled studies should be conducted focusing on clinical outcomes to determine the optimal dose of 4-PCC for VKAs reversal. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 17, 2021 Category: Cardiology Source Type: research

Cilostazol: a Review of Basic Mechanisms and Clinical Uses
AbstractPrimarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels. However, cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. It has been observed to exhibit antiplatelet, antiproliferative, vasodilatory, and ischemic-reperfusion protective properties. As such, cilostazol has been investigated for clinical use in a variety o...
Source: Cardiovascular Drugs and Therapy - April 16, 2021 Category: Cardiology Source Type: research

CHOP Increases TRIB3-Dependent miR-208 Expression to Potentiate Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating TIMP3 in Atherosclerosis
ConclusionTaken together, inhibition of CHOP may inhibit the proliferation and migration of VSMCs as well as reduce the levels of TC, TG, and LDL-C but increase the level of HDL-C through the TRIB3/miR-208/TIMP3 axis, thereby inhibiting the progression of atherosclerosis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 15, 2021 Category: Cardiology Source Type: research

Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases
AbstractCardiovascular diseases are the leading cause of morbidity and mortality worldwide. Genome-wide association studies (GWAS) are powerful epidemiological tools to find genes and variants associated with cardiovascular diseases while follow-up biological studies allow to better understand the etiology and mechanisms of disease and assign causality. Improved methodologies and reduced costs have allowed wider use of bulk and single-cell RNA sequencing, human-induced pluripotent stem cells, organoids, metabolomics, epigenomics, and novel animal models in conjunction with GWAS. In this review, we feature recent advancemen...
Source: Cardiovascular Drugs and Therapy - April 15, 2021 Category: Cardiology Source Type: research

Translating Cardiovascular Genomics to Clinical Practice
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 14, 2021 Category: Cardiology Source Type: research

The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review
AbstractAimIn recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of  novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and f...
Source: Cardiovascular Drugs and Therapy - April 13, 2021 Category: Cardiology Source Type: research

An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection
ConclusionResults indicate great potential of CAIX inhibitor for further application in myocardial hypoxia injury therapy. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 12, 2021 Category: Cardiology Source Type: research

Correction to: A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07183-1 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 12, 2021 Category: Cardiology Source Type: research

Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban —J-ELD AF Registry Subanalysis
AbstractPurposeAlthough direct oral anticoagulants are effective and safe in preventing stroke in atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with extremely low body weight (60 kg (n = 1019, 33.7%), 50 –60 kg (n = 1126, 37.2%), and
Source: Cardiovascular Drugs and Therapy - April 8, 2021 Category: Cardiology Source Type: research

Angio-Based Fractional Flow Reserve, Functional Pattern of Coronary Artery Disease, and Prediction of Percutaneous Coronary Intervention Result: a Proof-of-Concept Study
ConclusionOur results suggest that functional patterns of CAD based on pre-PCI QFR trace can predict the functional outcome after PCI.Clinical Trial RegistrationClinicalTrials.gov, number NCT02811796. Date of registration: June 23, 2016. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 8, 2021 Category: Cardiology Source Type: research

Role of Bempedoic Acid in Clinical Practice
AbstractMany patients do not achieve optimal low-density lipoprotein cholesterol (LDL-C) levels with statins alone; others are unable to tolerate statin therapy. Additional non-statin treatment options including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and bile acid sequestrants are often necessary to further reduce the risk of atherosclerotic cardiovascular disease. This review provides practical guidance as to the use of bempedoic acid to lower LDL-C and includes direction as to which patients may benefit and advice for safety monitoring during treatment. Bempedoic acid, a new class of agent, ...
Source: Cardiovascular Drugs and Therapy - April 5, 2021 Category: Cardiology Source Type: research

Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model
AbstractPurposeLeft atrial appendage (LAA) closure decreases atrial natriuretic peptide (ANP) levels, which indirectly increases the risk of arrhythmogenicity. We aimed to determine the effect of a combined angiotensin receptor-neprilysin inhibitor (ARNi) on arrhythmogenicity following LAA closure in an animal model.MethodsTwenty-four rabbits were randomized into four groups: (1) control, (2) LAA closure (LAAC), (3) heart failure (HF)-LAAC, and (4) HF-LAAC with sacubitril/valsartan (+ARNi). HF models were developed in the HF-LAAC and HF-LAAC+ARNi groups. Epicardial LAA exclusion was performed in the LAAC, HF-LAAC, and HF-L...
Source: Cardiovascular Drugs and Therapy - April 5, 2021 Category: Cardiology Source Type: research

Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial
ConclusionThis simple risk score stratifies patients with HFpEF by their baseline risk of cardiovascular death. Patients at very high risk derive great benefits from spironolactone therapy. This easy-to-use risk score provides a practical tool that can facilitate risk stratification and tailoring therapy for those who benefit most from spironolactone.Trial RegistrationClinicalTrials.gov Identifier: NCT00094302. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2021 Category: Cardiology Source Type: research

Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study
The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant for conversion of AF to sinus rhythm in daily practice.Methods and ResultsConsenting patients with symptomatic recent-onset AF (
Source: Cardiovascular Drugs and Therapy - March 25, 2021 Category: Cardiology Source Type: research

Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity
ConclusionOur works indicated that OCT retards progression of LVH through calcineurin-NFAT pathway, which reveal a novel aspect of OCT in attenuating pathological LVH. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 25, 2021 Category: Cardiology Source Type: research

Insulin Rescued MCP-1-Suppressed Cholesterol Efflux to Large HDL2 Particles via ABCA1, ABCG1, SR-BI and PI3K/Akt Activation in Adipocytes
In this study, we hypothesize that MCP-1 impairs cholesterol efflux of adipocytes to HDL2 and insulin rescues this process.MethodsWe recruited coronary artery disease (CAD) patients with obesity and overweight to analyze the association between MCP-1 and HDL2-C by Pearson correlation coefficients. We performed [3H]-cholesterol efflux assay to demonstrate the effect of MCP-1 and insulin on cholesterol efflux from 3T3-L1 adipocytes to large HDL2 particles. Western blot, RT-qPCR, cell-surface protein assay, and confocal microscopy were performed to determine the regulatory mechanism.ResultsPlasma MCP-1 concentrations were neg...
Source: Cardiovascular Drugs and Therapy - March 19, 2021 Category: Cardiology Source Type: research

Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding
ConclusionAmong patients with AF receiving anticoagulant treatment and with a prior history of upper GIB, PPI co-therapy was associated with a significant reduction in the risk of major GIB in patients treated with rivaroxaban and warfarin. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 17, 2021 Category: Cardiology Source Type: research

Efficacy and Safety of Clinically Driven Low-Dose Treatment with Direct Oral Anticoagulants in Asians with Atrial Fibrillation: a Systematic Review and Meta-analysis
AbstractPurposeAlthough clinically driven low-dose (CDLD) treatment with direct oral anticoagulants (DOACs) is frequently administered to Asian patients with atrial fibrillation, clinical evidence confirming its efficacy remains insufficient. We evaluated the clinical efficacy and safety of CDLD treatment with DOACs compared to on-label dose treatment in Asian patients with atrial fibrillation and assessed the differences in the baseline characteristics between patients receiving these treatments.MethodsWe searched the MEDLINE, CENTRAL, EMBASE, Web of Science, and Scopus databases for articles from inception through July 2...
Source: Cardiovascular Drugs and Therapy - March 16, 2021 Category: Cardiology Source Type: research

A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions
ConclusionsIn this prospective study, the DCB only strategy for de novo lesion was non-inferior to the new-generation DES in terms of 9-month late lumen loss. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 13, 2021 Category: Cardiology Source Type: research

Report of the British Society for Cardiovascular Research Inaugural Online Autumn Meeting 2020
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 13, 2021 Category: Cardiology Source Type: research

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction
Conclusion: New genetics-guided pharmacotherapies to reduce levels of triglycerides and TGRLs and thus reduce risk of CVD have been developed and will be discussed here. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 12, 2021 Category: Cardiology Source Type: research

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines
ConclusionThese data demonstrate that low-dose dasatinib exhibits desirable therapeutic PK properties that is sufficient for effective target engagement to ameliorate HCM progression in NSML mice. These data demonstrate that low-dose dasatinib treatment may be an effective therapy against HCM in NSML patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 10, 2021 Category: Cardiology Source Type: research

Restoring Perivascular Adipose Tissue Function in Obesity Using Exercise
ConclusionLoss of neutrally mediated PVAT anti-contractile function in obesity will contribute to the development of hypertension and type II diabetes. Exercise training will restore function and treat the vascular complications of obesity. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 9, 2021 Category: Cardiology Source Type: research

Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease
AbstractPurposeTo assess real-world data on the clinical implementation of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in cardiovascular patients and to investigate barriers to prescribe these agents.MethodsPatients presenting with coronary artery disease (CAD) and type 2  diabetes mellitus (T2DM) between 01/2014 and 04/2020 were included in the present analysis and followed prospectively. All first-time prescriptions of SGLT2i and GLP-1RA were identified.ResultsAmong 1498 patients with CAD and T2DM, 17.6% of patients received an SGLT2i and 5.5% a GLP-1RA....
Source: Cardiovascular Drugs and Therapy - March 5, 2021 Category: Cardiology Source Type: research

Is there a Future for Remote Ischemic Conditioning in Acute Myocardial Infarction?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 5, 2021 Category: Cardiology Source Type: research

Vitamin D 3 Supplementation Alleviates Left Ventricular Dysfunction in a Mouse Model of Diet-Induced Type 2 Diabetes: Potential Involvement of Cardiac Lipotoxicity Modulation
ConclusionThis work brought to light the beneficial effects of cholecalciferol supplementation, in secondary prevention, on cardiac remodeling and function in a mouse model of diet-induced type 2 diabetes. Those cardioprotective effects may be, at least in part, attributed to the modulation of myocardial levels of lipotoxic species by vitamin D. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 4, 2021 Category: Cardiology Source Type: research

Evaluating a Simple Approach to Identify Adults Meeting the 2018 AHA/ACC Cholesterol Guideline Definition of Very High Risk for Atherosclerotic Cardiovascular Disease
ConclusionThe vast majority of patients with a recent ACS, history of MI, ischemic stroke, or symptomatic PAD meet the 2018 AHA/ACC cholesterol guideline definition of very high risk. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 4, 2021 Category: Cardiology Source Type: research

Prediction of the Individual Risk of Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 4, 2021 Category: Cardiology Source Type: research

Correction to: Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07164-4 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 4, 2021 Category: Cardiology Source Type: research

Innovations in Cardiac Implantable Electronic Devices
AbstractCardiac implantable electronic devices (CIEDs) are essential for the management of a variety of cardiac conditions, including tachyarrhythmias, bradyarrhythmias, and medically refractory heart failure (HF). Recent advancements in CIED technology have led to innovative solutions that overcome shortcomings associated with traditional devices or address unmet needs. Leadless pacemakers, subcutaneous implantable cardioverter defibrillators (ICDs), and extravascular ICDs eliminate lead-related complications common with conventional pacemakers or ICDs. Conduction system pacing (His bundle pacing and left bundle branch pa...
Source: Cardiovascular Drugs and Therapy - March 2, 2021 Category: Cardiology Source Type: research

The Protective Role of Bmal1-Regulated Autophagy Mediated by HDAC3/SIRT1 Pathway in Myocardial Ischemia/Reperfusion Injury of Diabetic Rats
ConclusionBased on these findings, the disordered HDAC3/SIRT1 circuit (upregulated HDAC3 and downregulated SIRT1 levels) plays an important role in aggravating myocardial IR injury in diabetic rats by downregulating Bmal1-mediated autophagy. Treatments targeting HDAC3/SIRT1 to activate the autophagy may represent a novel strategy to alleviate myocardial IR injury in diabetes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 23, 2021 Category: Cardiology Source Type: research

Generation of a Novel In Vitro Model to Study Endothelial Dysfunction from Atherothrombotic Specimens
ConclusionsCEO cells can be reliably isolated and cultured from thrombectomy specimens in patients with acute coronary syndrome. Compared to controls, patient-derived coronary endothelial cells had impaired capacity to proliferate, migrate, and contribute to angiogenesis. CEO cells could be used to identify novel therapeutic targets to enhance endothelial function and prevent acute coronary syndromes. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 20, 2021 Category: Cardiology Source Type: research

Targeting Human lncRNAs for Treating Cardiometabolic Diseases
ConclusionsDysregulation of lncRNAs has been associated with human diseases, including cancer, neurodegenerative, and cardiometabolic diseases. However, as lncRNAs are usually much less conserved than mRNAs at the sequence level, most human lncRNAs are either primate or human specific. The pathophysiological significance of human lncRNAs is still mostly unclear due to the persistent limitations in studying human-specific genes. This review will focus on recent discoveries showing human lncRNAs ’ roles in regulating metabolic homeostasis and the potential of targeting this unique group of genes for treatment of cardio...
Source: Cardiovascular Drugs and Therapy - February 20, 2021 Category: Cardiology Source Type: research

Translating genetic association of lipid levels for biological and clinical application
ConclusionsLipids are one of the most successful group of traits in the era of genome-wide genetic discovery for identification of novel loci and plausible drug targets. However, a substantial fraction of lipid trait heritability remains unexplained. Further analysis of diverse ancestries and state of the art methods for association locus refinement could potentially reveal some of this missing heritability and increase the clinical application of the genomic association results. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 19, 2021 Category: Cardiology Source Type: research

A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database
ConclusionPharmacovigilance studies allow an essential opportunity to evaluate the safety profile of CVD medications in clinical practice. Additional research is needed to evaluate these reported safety concerns for recently approved CVD medications. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 18, 2021 Category: Cardiology Source Type: research

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19
ConclusionThis large multicenter retrospective of Covid-19 patients with hypertension found a reduced mortality among CCB and beta-blockers users, suggesting a putative protective effect. Our findings did not show any association between the use of renin-angiotensin-aldosterone system inhibitors and the risk of in-hospital death. Although they need to be confirmed in further studies, these results support the continuation of antihypertensive agents in patients with Covid-19, in line with the current guidelines. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 17, 2021 Category: Cardiology Source Type: research

Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter Aortic Valve Implantation, Updated Meta-Analysis
ConclusionsThis meta-analysis supports the use of aspirin as the optimal antiplatelet strategy following TAVI procedures in reducing bleeding without an increase in ischemic events compared with dual antiplatelet therapy. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 15, 2021 Category: Cardiology Source Type: research

Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis
AbstractBackgroundThe current American College of Cardiology and American Heart Association (ACC/AHA) guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 6  months followed by lifelong aspirin after transcatheter aortic valve replacement (TAVR). However, studies that have DAPT with aspirin following TAVR have questioned this recommendation as DAPT has been associated with more bleeding events compared to aspirin. We performed a systematic review and m eta-analysis of all the RCTs comparing DAPT (aspirin plus clopidogrel) with aspirin alone as antithrombotic treatment following transc...
Source: Cardiovascular Drugs and Therapy - February 11, 2021 Category: Cardiology Source Type: research

Cost-Effectiveness of Endovascular Versus Open Repair of Abdominal Aortic Aneurysm: A Systematic Review
ConclusionAccording to the results, the EVAR technique has been more cost-effective than OSR for high-risk patients, but the need for continuous follow-up, increased costs, and re-intervention over the long term and for low-risk patients has reduced the cost-effectiveness of this method. As the health systems vary among different countries (i.e. quality of care, cost of devices, etc.), and due to the heterogeneity of studies in terms of the follow-up period, time horizon, and threshold, all of which are inherent features of economic evaluation, generalizing the results should be done with much caution, and policymaking mus...
Source: Cardiovascular Drugs and Therapy - February 9, 2021 Category: Cardiology Source Type: research

LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry
AbstractPurposeLow-density lipoprotein (LDL) cholesterol reduction by statin therapy is dose-dependent, varies among different statins, and has wide inter-individual variability. The present study aimed to compare mean LDL cholesterol reduction and its variability achieved with different doses of the three statins most frequently used in monotherapy or combined with ezetimibe in a real clinical setting.MethodsOf 5620 cases with primary hypercholesterolemia on the Spanish Arteriosclerosis Society Registry, 1004 with non-familial hypercholesterolemia and complete information on drug therapy and lipid profile were included.Re...
Source: Cardiovascular Drugs and Therapy - February 8, 2021 Category: Cardiology Source Type: research

Effects of OP2113 on Myocardial Infarct Size and No Reflow in a Rat Myocardial Ischemia/Reperfusion Model
AbstractPurposeThe present study was to determine whether OP2113 could limit myocardial infarction size and the no-reflow phenomenon in a rat myocardial ischemia/reperfusion model.MethodsRat heart –isolated mitochondria (RHM) were used to investigate mitochondrial respiration and mitochondrial reactive oxygen species (mtROS) generation both in normal conditions and in ischemia/reperfusion-mimicking conditions (using high concentrations of succinate). Human skeletal muscle myoblasts (HSMM) i n culture were used to investigate the cellular intermittent deprivation in energy substrates and oxygen as reported in ischemia...
Source: Cardiovascular Drugs and Therapy - February 8, 2021 Category: Cardiology Source Type: research

Correction to: The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07152-8 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 5, 2021 Category: Cardiology Source Type: research

Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4 –5 Chronic Kidney Disease or on Dialysis
ConclusionsCurrent evidence suggests that rivaroxaban or apixaban are safe and at least as effective as warfarin in patients with AF and stage 4 –5 CKD or on dialysis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 4, 2021 Category: Cardiology Source Type: research